Compare SWBI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | LYEL |
|---|---|---|
| Founded | 1852 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.4M | 556.1M |
| IPO Year | 2000 | 2021 |
| Metric | SWBI | LYEL |
|---|---|---|
| Price | $14.56 | $19.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $14.00 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 405.2K | 60.9K |
| Earning Date | 06-17-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | $36,000.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | $8,712.13 |
| P/E Ratio | $291.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.73 | $0.40 |
| 52 Week High | $15.79 | $45.00 |
| Indicator | SWBI | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 38.13 |
| Support Level | $13.80 | $15.82 |
| Resistance Level | $15.24 | $27.30 |
| Average True Range (ATR) | 0.41 | 1.43 |
| MACD | -0.12 | -0.33 |
| Stochastic Oscillator | 18.00 | 5.12 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.